Overview

Efficacy and Safety Study of Oxaliplatin/5-FU in Patients With Recurrent or Metastatic Head and Neck Cancer

Status:
Terminated
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
To evaluate the objective response rate of oxaliplatin combined with 5-FU in patients with recurrent or metastatic head and neck cancer and to assess the safety profile of these treatment regimen.
Phase:
Phase 2
Details
Lead Sponsor:
Nang Kuang Pharmaceutical Co., Ltd.
Treatments:
Oxaliplatin